Professor George Birkmayer MD PhD
Ph.D. in Biochemistry, University of Vienna, Austria
M.D. from the University of Munich
Associate Professor for Cell Biology, University of Munich,
Research Fellow with Prof. Michael  Bishop, Dept. Microbiology, UCSF
in 1976. Guest Lecturer at Universities in New York, Philadelphia, Montreal
Since 1982 Professor for Medical Chemistry, University of Graz, Austria
and Medical director of the Birkmayer Laboratories, Vienna, Austria.
Since 1989 he is a visiting Professor at the Universities of Beijing, Guangzhou and Xi’An(China). He is a Fellow of the American College of Nutrition and since 2005 President of the Int. Academy of Tumour Marker Oncology(IATMO), New York.

2007 - COENZYME 1 (NADH): THE ONLY REAL FUEL FOR CELLULAR ENERGY WITH A SCIENTFICALLY PROVEN ANTI-AGING EFFECT.

Coenzyme-1 (N.A.D.H.) is one of the  most  important  coenzyme  catalyzing
more  than a thousand of metabolic reactions in the human body, the most
important  of which  is the production of  ATP (Adenosin-Tri-Phosphate)
The more ATP energy a cell  has  available  the better it can function and
the   longer  it can live. The question  is  can  we  increase  the ATP production
in  the cells by  exposing them to  coenzyme-1 (NADH).  The answer is yes, we can,
as   has been shown  on isolated heart cells.  When hearts cells are incubated
with   NADH  a 30% increase in ATP production  is observed (1). Due to this the  
vitality and lifespan of these heart cells  are increased.  (
The  same observation  was made  with red   blood cells.  This  discovery  has
 Implications  for the shelf life of  blood donation  and  also for the extension of
 preservation time of transplantable organs .
A  patent  for  this effect of NADH is pending.  This heart cell  system  allows to test
other   coenzymes  and substances for which an energy increasing effect has been claimed.  From all the substances tested so far  including  NAD (the oxidized form of NADH), Nicotinamide (Vitamine B3), Coenzyme Q10, Creatine, Carnitine , Caffeine  only
NADH  does  increase  ATP production in these cells.
NADH as biological form of hydrogen is a very sensitive substance which degrades
rapidly   even in dry state when blended with lactose the most common ingredient of
drugs.  The author succeeded in  stabilizing  NADH  and transposing it into a  tablet form
in  which NADH is stable for  at least 2 years.  This formulation, patented world-wide   is  commercially available under the brand name ENADA™.
Based on the patent protection of this product   numerous   GCP studies have been performed
in the U.S. as well as in Europe. In  an  FDA  approved  double-blind placebo controlled study
it was found that  NADH  leads to an improvement of certain cognitive functions in patients
with  Alzheimer dementia. (2) . Another FDA  approved  double blind study  with patients suffering  from CFS (Chronic Fatigue Syndrome)  revealed  more than 80 % of the patients
were  relieved  from their fatigue after a 6 month treatment period with 10 mg NADH per day.

In a  further study  the  effect  of NADH  on cognitive performance  of healthy middle aged individuals  after sleep deprivation for 24 hours  was tested   at Cornell University.
Subjects taking 20 mg of  NADH did not only better in terms of cognitive performance than the placebo subjects  but  did more than 3 times better than the same subjects  at base line,
after  a full night sleep (3). In other words,   NADH  enhances cognitive performance in healthy  individuals  and  due to its energy-increasing effect for the brain it  may  prevent  MCI (Mild Cognitive Impairment)  as well as   Alzheimer dementia.
As  most  cancer  cells  exhibit   an ATP deficiency  and   NADH  can increase ATP energy in  cells  this coenzyme was given to  cancer patients in an open label trial.  17  prostate cancer
patients with  pathologically proven carcinoma have been cured in  3 to 5 months with a daily dose of  40 mg NADH.  A  number  of  patients  with  mammary carcinoma  and
small cell lung cancer  have  been cured  in between  6 months with the  same daily dose
of  NADH.(4) More than  6o  cancer  patients have been treated so far with NADH most of them are disease free or  show no  tumour progression.  The   increase in physical  and  mental  energy  was  reported  from  all the cancer patients  taking NADH.
The   mechanism of action of  NADH  is  based on  the   elevation of the intracellular ATP.
Hence   NADH   may   be  a reasonable approach  for many  ailments particular those based
on   mitochondrial  dysfunctions.
   
References:
(1)  Pelzmann, B., et al., Brit.J.Pharm.2003, 139, 749-754
(2)  Demarin, V. et al. Drugs Exptl. Clin. Res. 2004 ,XXX , 27-33
(3)  Moline, ML. Et al. Abstr.1st Int. Conf. Mech. Action Nutraceuticals 2001
(4)  Forsyth, L.M., et al. Ann.Allergy Asthma  Immun. 1999, 82, 185-191
(5)  Birkmayer, G., and Zhang, J. in Bagchi,D. and Preuss H.G. “Phytopharmaceuticals
       in  Cancer  Chemoprevention , CRC Press 2005, 541-554